Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Acid Ceramidase Deficiency in Mice Results in a Broad Range of Central Nervous System Abnormalities

J. Sikora, S. Dworski, EE. Jones, MA. Kamani, MC. Micsenyi, T. Sawada, P. Le Faouder, J. Bertrand-Michel, A. Dupuy, CK. Dunn, ICY. Xuan, J. Casas, G. Fabrias, DR. Hampson, T. Levade, RR. Drake, JA. Medin, SU. Walkley,

. 2017 ; 187 (4) : 864-883.

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc17023177

Farber disease is a rare autosomal recessive disorder caused by acid ceramidase deficiency that usually presents as early-onset progressive visceral and neurologic disease. To understand the neurologic abnormality, we investigated behavioral, biochemical, and cellular abnormalities in the central nervous system of Asah1(P361R/P361R) mice, which serve as a model of Farber disease. Behaviorally, the mutant mice had reduced voluntary locomotion and exploration, increased thigmotaxis, abnormal spectra of basic behavioral activities, impaired muscle grip strength, and defects in motor coordination. A few mutant mice developed hydrocephalus. Mass spectrometry revealed elevations of ceramides, hydroxy-ceramides, dihydroceramides, sphingosine, dihexosylceramides, and monosialodihexosylganglioside in the brain. The highest accumulation was in hydroxy-ceramides. Storage compound distribution was analyzed by mass spectrometry imaging and morphologic analyses and revealed involvement of a wide range of central nervous system cell types (eg, neurons, endothelial cells, and choroid plexus cells), most notably microglia and/or macrophages. Coalescing and mostly perivascular granuloma-like accumulations of storage-laden CD68(+) microglia and/or macrophages were seen as early as 3 weeks of age and located preferentially in white matter, periventricular zones, and meninges. Neurodegeneration was also evident in specific cerebral areas in late disease. Overall, our central nervous system studies in Asah1(P361R/P361R) mice substantially extend the understanding of human Farber disease and suggest that this model can be used to advance therapeutic approaches for this currently untreatable disorder.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023177
003      
CZ-PrNML
005      
20170830102039.0
007      
ta
008      
170720s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ajpath.2016.12.005 $2 doi
035    __
$a (PubMed)28342444
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Sikora, Jakub $u Dominick P. Purpura Department of Neuroscience, Rose F. Kennedy Intellectual and Developmental Disabilities Research Center, Albert Einstein College of Medicine, Bronx, New York; Institute of Inherited Metabolic Disorders, Charles University, 1st Faculty of Medicine, Prague, Czech Republic; Institute of Pathology, Charles University, 1st Faculty of Medicine, Prague, Czech Republic.
245    10
$a Acid Ceramidase Deficiency in Mice Results in a Broad Range of Central Nervous System Abnormalities / $c J. Sikora, S. Dworski, EE. Jones, MA. Kamani, MC. Micsenyi, T. Sawada, P. Le Faouder, J. Bertrand-Michel, A. Dupuy, CK. Dunn, ICY. Xuan, J. Casas, G. Fabrias, DR. Hampson, T. Levade, RR. Drake, JA. Medin, SU. Walkley,
520    9_
$a Farber disease is a rare autosomal recessive disorder caused by acid ceramidase deficiency that usually presents as early-onset progressive visceral and neurologic disease. To understand the neurologic abnormality, we investigated behavioral, biochemical, and cellular abnormalities in the central nervous system of Asah1(P361R/P361R) mice, which serve as a model of Farber disease. Behaviorally, the mutant mice had reduced voluntary locomotion and exploration, increased thigmotaxis, abnormal spectra of basic behavioral activities, impaired muscle grip strength, and defects in motor coordination. A few mutant mice developed hydrocephalus. Mass spectrometry revealed elevations of ceramides, hydroxy-ceramides, dihydroceramides, sphingosine, dihexosylceramides, and monosialodihexosylganglioside in the brain. The highest accumulation was in hydroxy-ceramides. Storage compound distribution was analyzed by mass spectrometry imaging and morphologic analyses and revealed involvement of a wide range of central nervous system cell types (eg, neurons, endothelial cells, and choroid plexus cells), most notably microglia and/or macrophages. Coalescing and mostly perivascular granuloma-like accumulations of storage-laden CD68(+) microglia and/or macrophages were seen as early as 3 weeks of age and located preferentially in white matter, periventricular zones, and meninges. Neurodegeneration was also evident in specific cerebral areas in late disease. Overall, our central nervous system studies in Asah1(P361R/P361R) mice substantially extend the understanding of human Farber disease and suggest that this model can be used to advance therapeutic approaches for this currently untreatable disorder.
650    _2
$a kyselá ceramidasa $x metabolismus $7 D055573
650    _2
$a zvířata $7 D000818
650    _2
$a chování zvířat $7 D001522
650    _2
$a centrální nervový systém $x abnormality $x patologie $7 D002490
650    _2
$a mozeček $x patologie $x ultrastruktura $7 D002531
650    _2
$a velký mozek $x patologie $x ultrastruktura $7 D054022
650    _2
$a Farberova nemoc $x komplikace $x patologie $7 D055577
650    _2
$a homozygot $7 D006720
650    _2
$a hydrocefalus $x patologie $7 D006849
650    _2
$a myši $7 D051379
650    _2
$a myši transgenní $7 D008822
650    _2
$a pohybová aktivita $7 D009043
650    _2
$a malformace nervového systému $x etiologie $x patologie $7 D009421
650    _2
$a neurony $x patologie $x ultrastruktura $7 D009474
650    _2
$a fenotyp $7 D010641
650    _2
$a spektrometrie hmotnostní - ionizace laserem za účasti matrice $7 D019032
650    _2
$a sfingolipidy $x metabolismus $7 D013107
650    _2
$a časové faktory $7 D013997
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dworski, Shaalee $u Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
700    1_
$a Jones, E Ellen $u Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina.
700    1_
$a Kamani, Mustafa A $u University Health Network, Toronto, Ontario, Canada.
700    1_
$a Micsenyi, Matthew C $u Dominick P. Purpura Department of Neuroscience, Rose F. Kennedy Intellectual and Developmental Disabilities Research Center, Albert Einstein College of Medicine, Bronx, New York.
700    1_
$a Sawada, Tomo $u Dominick P. Purpura Department of Neuroscience, Rose F. Kennedy Intellectual and Developmental Disabilities Research Center, Albert Einstein College of Medicine, Bronx, New York.
700    1_
$a Le Faouder, Pauline $u MetaToul-Lipidomic Facility-MetaboHUB, INSERM UMR1048, Institute of Cardiovascular and Metabolic Diseases, Université Paul Sabatier-Toulouse III, Toulouse, France.
700    1_
$a Bertrand-Michel, Justine $u MetaToul-Lipidomic Facility-MetaboHUB, INSERM UMR1048, Institute of Cardiovascular and Metabolic Diseases, Université Paul Sabatier-Toulouse III, Toulouse, France.
700    1_
$a Dupuy, Aude $u MetaToul-Lipidomic Facility-MetaboHUB, INSERM UMR1048, Institute of Cardiovascular and Metabolic Diseases, Université Paul Sabatier-Toulouse III, Toulouse, France.
700    1_
$a Dunn, Christopher K $u University Health Network, Toronto, Ontario, Canada.
700    1_
$a Xuan, Ingrid Cong Yang $u Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada.
700    1_
$a Casas, Josefina $u Research Unit on Bioactive Molecules, Department of Biomedicinal Chemistry, Institute for Advanced Chemistry of Catalonia, Spanish National Research Council, Barcelona, Spain.
700    1_
$a Fabrias, Gemma $u Research Unit on Bioactive Molecules, Department of Biomedicinal Chemistry, Institute for Advanced Chemistry of Catalonia, Spanish National Research Council, Barcelona, Spain.
700    1_
$a Hampson, David R $u Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada.
700    1_
$a Levade, Thierry $u INSERM UMR1037, Cancer Research Center of Toulouse, Universite Toulouse III Paul-Sabatier, Toulouse, France; Metabolic Biochemistry Laboratory, Federative Institute of Biology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
700    1_
$a Drake, Richard R $u Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina.
700    1_
$a Medin, Jeffrey A $u Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; University Health Network, Toronto, Ontario, Canada; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address: jmedin@mcw.edu.
700    1_
$a Walkley, Steven U $u Dominick P. Purpura Department of Neuroscience, Rose F. Kennedy Intellectual and Developmental Disabilities Research Center, Albert Einstein College of Medicine, Bronx, New York. Electronic address: steve.walkley@einstein.yu.edu.
773    0_
$w MED00009121 $t The American journal of pathology $x 1525-2191 $g Roč. 187, č. 4 (2017), s. 864-883
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28342444 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170830102627 $b ABA008
999    __
$a ok $b bmc $g 1238858 $s 984090
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 187 $c 4 $d 864-883 $i 1525-2191 $m American journal of pathology $n Am J Pathol $x MED00009121
LZP    __
$a Pubmed-20170720

Find record

Citation metrics

Archiving options